Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,953 total articles
Arm's debut of a physical AI CPU with marquee customers has re-rated the stock. With $165.3B market cap, strong technical momentum, and a clear path to higher royalties and chip sales, I put forward a mid-term bullish swing trade (45 trading days) with an entry at $150, stop at $135, and an initial target of $185. The thesis balances execution risk…
Astronics (ATRO) has patched several near-term execution issues and added targeted revenue from bolt-on deals. With a $2.48B market cap, improving free cash flow and a growing aircraft lighting and electrical-systems market, the risk/reward looks favorable for a mid-term trade. I recommend a controlled long position with a stop below recent support…
American Superconductor (AMSC) is a small-cap power-electronics and grid-resilience play that has started to re-rate after a string of operational wins and a strategic acquisition. The stock is trading at $32.99 with improving technicals, 2025 revenue momentum, and a strengthened product portfolio after the Comtrafo deal. This trade idea outlines a…
Black Diamond Therapeutics (BDTX) is a small-cap oncology developer with a focused bet on BDTX-1535, a brain-penetrant EGFR MasterKey inhibitor. The market has largely shrugged at recent clinical and licensing news; valuation metrics and a modest float create a tradeable, asymmetric risk-reward. I outline a long trade with clear entry, stop and tar…
Cal‑Maine (CALM) is an underappreciated cash machine trading at single‑digit multiples. Ahead of earnings, the stock offers a compelling mid‑term long trade: buy at current levels, stop tight under the winter low, target a re-rating toward a conservative multiple as recent M&A and prepared‑foods expansion start to show through.
Microsoft (MSFT) is trading near its 52-week low after a heavy sell-off tied to AI capex and margin worries. With a $2.77T market cap, strong free cash flow ($77.4B trailing), low leverage (debt/equity ~0.10) and an oversold technical picture (RSI ~28), the pullback looks like a high-probability long setup. This trade pairs a tactical entry at $376…
Citizens Financial Services (CZFS) trades at roughly $60.66 with a P/E near 8 and P/B below 1, yet reported meaningful net income gains in 2025 driven by higher net interest income and lower credit loss provisions. If interest rates begin a sustained decline, CZFS's combination of improving fundamentals, a 3.26% yield and a compact float makes it a…
Duke Energy's regulated footprint across the Carolinas and Florida, growing capital plan, and reliable dividend create a favorable risk/reward as AI data center demand lifts Sunbelt power consumption. Valuation is reasonable for a regulated utility, balance sheet leverage is the primary watch item, and near-term catalysts could drive a re-rating to…
First Watch (FWRG) finished fiscal 2025 with heavy unit growth, positive same-restaurant sales and traffic, and a system of 633 restaurants. The stock trades at roughly $11.45 with a market cap near $700M, EV/EBITDA ~9.3 and a P/E north of 36. For investors willing to look out 6+ months, this combination of growth and reasonable enterprise multiple…
Aeluma is shifting from lab-scale IP to wafer-scale photonic manufacturing. Recent capital raises, equipment purchases, and government contract wins materially de-risk the path to commercialization. The risk-reward is asymmetric for disciplined traders: expensive on sales today but potentially re-rated if production-ready demos and incremental reve…
Crescent Energy (CRGY) looks like a mid-cap shale operator the market has underpriced. With a roughly $4.29B market cap, an accretive Vital Energy tie-up, attractive EV/EBITDA and P/B multiples, and a 3%+ yield, Crescent offers a favorable risk/reward for a long trade over the next 180 trading days. The plan: buy at $13.08, stop at $11.20, target $…
Booking Holdings has been punished on fears of AI disruption and a busy news cycle around a 25-for-1 stock split. The underlying business remains cash-generative, with trailing free cash flow near $9.1B and a market cap of roughly $136B. Technicals show an orderly dip and momentum turning constructive; valuation metrics and a healthy FCF yield argu…
GE Aerospace combines high-margin aftermarket revenue, strong free cash flow and targeted manufacturing investments that should translate into durable growth. At a market cap near $305B and free cash flow of $7.26B, the stock carries a premium multiple but has several clear catalysts - expanding MRO programs, defense wins and AI-driven maintenance …
Voyager Technologies is showing tangible defense revenue momentum and progressing Starlab toward manufacturing after a Commercial Critical Design Review. The stock has pulled back into technical support and carries material upside if NASA awards contracts or Starlab validation continues. We recommend a mid-term long trade with strict risk controls …
Boston Scientific (BSX) is under pressure after a sharp earnings-driven selloff and multiple securities class action filings, but technical oversold conditions, a healthy free cash flow profile ($3.66B), and manageable leverage argue for a measured tactical long. This is a rated-up trade idea: enter around $68.60, stop at $64.00, and target $82.00 …
Amplitude's stock has been punished into the low single digits but the underlying business is showing signs of healthier unit economics: recent quarterly revenue acceleration, notable free cash flow and product-led AI momentum. With a market cap around $900M and $192M of cash plus a $100M buyback authorization, the risk-reward favors a measured lon…
Pfizer offers a compelling short-to-mid-term trade: the stock sits near technical support, yields ~6.3%, and the company produces meaningful free cash flow ($10.375B). With a market cap of roughly $153.4B and an EV/EBITDA of 9.06, the risk-reward for a mid-term rebound is attractive. This note lays out an entry at $26.70, a $30.00 target (45 tradin…
Booking Holdings (BKNG) has been sold off on headlines about AI threats to online travel agencies. Fundamentals remain strong - $135.9B market cap, $9.09B free cash flow, and EPS of $170.62 - while technicals show recent support near $4,000. We upgrade to Buy and propose an actionable long trade with a $4,340 entry, $3,900 stop and $5,900 target ov…
CAREVIEW COMMUNS (CRVW) is an ultralow-priced OTC stock showing renewed momentum and meaningful short interest. This trade idea outlines a mid-term, structured long: entry at current levels, tight stop, and a larger profit target to reflect the speculative upside if volume and short-covering accelerate.
Dollarama (DLMAF) plunged into oversold territory after a sharp post-quarter selloff. The OTC-listed shares show stretched negativity — RSI 26, price below the 10/20/50 SMAs, and very high short-volume on 03/24/2026 — creating a risk-reward setup for a long trade. This idea is tactical: enter near $120, limit downside with a $104 stop, and aim for …
DHT's balance-sheet improvement from recent VLCC sales and the arrival of newbuildings into the spot market materially increases the company's optionality for a large Q2 cash distribution. Shares trade at $18.64 with a market cap near $2.97B and a PE of 13.5; a disciplined mid-term long can capture upside if management leans into a special/boosted …
Santander trades near $11 with a market cap of $160B and a trailing P/E ~10.9. Recent noise around a UK mortgage exposure and legal inquiries has pressured sentiment. Under the surface, a diversified franchise, improving risk-weighted asset mix, and strategic initiatives in payments and digital banking argue for earnings recovery and multiple re-ra…
Micron beat fiscal Q2 estimates handily, but guidance and a heavy capex cadence create a trap for momentum buyers. At roughly $446B market cap and ~19x reported EPS, the stock is richly priced vs cyclical memory risk. This trade idea lays out a mid-term short: enter at $400.01, target $320.00, stop $428.00, horizon 45 trading days.
Azenta's business sits in an expanding biopreservation market, but recent price action, negative earnings, weakening moving averages and elevated short activity signal limited upside near-term. We recommend a tactical short with defined entry, stop and target over a mid-term horizon (45 trading days).
Blue Owl (OWL) has been punished on private credit redemption headlines and short-term liquidity worries. Fundamentals — significant free cash flow, a sub-$10B enterprise value and an oversold technical set-up — argue for a tactical long. This trade lays out exact entry, stop and target with a 45 trading-day horizon and clear risk controls.
